

January 25, 2022

Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai – 400 001.

Dear Sir,

Sub: Open Offer for acquisition of upto 74,59,400 Equity Shares of Rs. 10/- each of Lyka Labs Limited ("Target Company") by Ipca Laboratories Limited ("Acquirer") under Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011 ("SEBI SAST Regulations")

This has reference to the Open Offer made by the Acquirer to the shareholders of Lyka Labs Limited ("Target Company") under the SEBI SAST Regulations.

In terms of Regulation 18(7) of the SEBI SAST Regulations, on behalf of the Acquirer, we have issued the Open Offer opening announcement and the same has been published today in the following publications

- 1. Business Standard, English and Hindi, all India editions
- 2. Mumbai Lakshadeep, Mumbai edition
- 3. Loksatta-Jansatta, Ankleshwar edition

In compliance of Regulation 18(7)(b) of the SEBI SAST Regulations, we have enclosed the relevant cutting of the newspaper wherein the Offer Opening Announcement has appeared.

Thanking you,

Yours faithfully, For **Arihant Capital Markets Limited** (SEBI Registration No. INM000011070)

Amol Kshirsagar Vice President - Merchant Banking

Encl: as above

## LYKA LYKA LABS LIMITED

## CIN : L24230GJ1976PLC008738 Regd Office : 4801 / B & 4802 / A, GIDC Industrial Estate, Ankleshwar, Gujarat, 393002

OFFER OPENING PUBLIC ANNOUNCEMENT For the attention of Equity Shareholders of

Corporate Office: Ground Floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai-400 036

Tel: 022-66112200 / 290 e-mail: enquiry@lykalabs.com

This is not a competing offer. There has been no competing offer to this Offer.

2.

5.

6.

7.

2

3.

4.

5.

8.

9

10.

Activity

broker

incorporated in the LOF

Schedule of Activities:

**Public Announcement Date** Detailed Public Statement Date

Last date for competing offer SEBI observations on draft LOF

the LOF shall be sent)

would be completed

er accepts full re

MANAGER TO THE OFFER **Arihant**Capital Arihant Capital Markets Limited anking Divis SEBI REGN NO.: INM 000011070 Validity : Permanent #1011, Solitaire Corporate Pa Andheri (E), Mumbai 400 093

Date: January 25, 2022 Place: Mumbai

obligations laid down in the SEBI SAST Regulations.

Tel: 022-42254800: Fax: 022-42254880

The Acq

Filing of Draft Letter of Offer with SEBI

Issue Opening Advertisement Date

Company.

(relevant extracts) on the offer:

accordance with the SEBI SAST Regulations.

FOR THE ATTENTION OF THE SHAREHOLDERS

original share certificate(s):

Settlement" on page 25 of the LOF.

(b) Mumbai Lakshadeep, Mumbai Marathi edition; and (c) Loksatta-Jansatta, Ankleshwar edition. The offer price is Rs. 130.50 per Equity Share. There has been no revision in the offer price.

This advertisement is being issued by Arihant Capital Markets Limited, Manager to the Offer on behalf of Ipca Laboratories Limited ("Acquirer") pursuant to Regulation 18(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011, as amended ("SEBI SAST Regulations") in respect of Open Offer to acquire up to 74,59,400 Equity Shares of face value Rs. 10/- each ("the Open Offer"), constituting 26% of the fully diluted voting Equity Share Capital of LYKA LABS LIMITED ("Target Company"). The

Detailed Public Statement ("DPS") with respect to the aforementioned Offer and corrigendum to the DPS was published on December 1, 2021 and on January 20, 2022, respectively, in (a) Business Standard, all India English & Hindi editions;

The Committee of Independent Directors (IDC) of the Target Company have issued following recommendation

IDC have reviewed the Public Announcement dated November 24, 2021, Detailed Public Statement and the Draft Letter of Offer filed with SEBI and looked at the Negotiated Price and Volume Weighted Average Price of the Target Company for a period of 60 trading days immediately preceding the date of the Public Announcement and was convinced that the offer price Rs. 130.50 per Equity Share is highest of both the values and is computed in

Based on the above, the IDC is of opinion that offer price to the shareholders of the Target Company is fair and reasonable. However shareholders are advised to independently evaluate the Offer and take informed decision. Recommendation of IDC of the Target Company was published on January 19, 2022 in Business Standard (English & Hindi all editions); Mumbai Lakshadeep, Mumbai edition; and Loksatta-Jansatta, Ankleshwar edition.

The despatch of the Letter of Offer (LOF) has been completed on January 19, 2022 to all the registered Shareholders of the Target Company whose email / postal addresses are available as per the records of the Target

Please note that a copy of the LOF (including Form of Acceptance/Tender Form) will also available on

Securities and Exchange Board of India ("SEBI") website (http://www.sebi.gov.in/). Registered / unregistered Shareholders or shareholders who may not have received the LOF for any reason whatsoever, if they so desire, may also apply on the Form of Acceptance/Tender Form downloaded from SEBI's website.

SEBI vide circular no. CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 as amended via SEBI circular CFD/DCR2/CIR/P/2016/131 dated December 09, 2016 and SEBI/HO/CFD/DCR-III/CIR/P/2021/615 dated August 13, 2021, has provided guidelines on the mechanism for acquisition of shares through the stock exchange pursuant to, inter alia, tender-offers under SEBI (SAST) Regulations, to facilitate tendering of shares by the shareholders and settlement of the same through the stock exchange mechanism. Accordingly, this Offer is being

carried out through the stock exchange mechanism (in the form of a separate acquisition window provided by BSE, being the designated stock exchange), and hence would be subject to payment of securities transaction tax (STT).In case of non-receipt/non-availability of the Form of Acceptance-cum-Acknowledgement / Tender Form (FOA), the application can be made on plain paper along with the following details:

number, DP name, DP ID number, number of Equity Shares tendered, investment status etc.

numbers, folio nos. number of shares tendered etc. and enclosing:

original shareholder has deceased, etc., as applicable.

statutory approvals that may become applicable at a later date.

Identified Date (for the purpose of determining the shareholders to whom

Date by which LOF will be despatched to the shareholders

Date of commencement of tendering period (open date) Date of expiry of tendering period (closure date)

Issued by: Manager to the Offer on behalf of the Acquirer:

Email: mbd@arihantcapital.com / Website: www.arihantcapital.com Contact Persons: Mr. Amol Kshirsagar / Mr. Satish Kumar P

Last date by which the Board of TC shall give its recommendation

Date by which all requirements including payment of consideration

 $self\text{-}attested\ copy\ of\ the\ shareholder's\ PAN\ Card\ (including\ the\ joint\ holders); and$ 

 $(although\,attested), such plain\,paper\,applications\,are\,liable\,to\,be\,rejected\,under\,this\,Offer$ 

For Equity Shares held in demat form: All eligible Shareholders may participate in the Offer by approaching their broker indicating the details of Equity Shares they intend to tender in Offer by providing their application in plain paper in writing signed by all Shareholders, stating names of all shareholders, address, client ID

In case of Equity Shares held in physical form: In accordance with the FAQs issued by SEBI "FAQs Tendering of Physical Shares in buyback offer / open offer / exit offer / delisting" dated February 20, 2020 and SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/ P/2020/144 dated July 31, 2020, shareholders holding shares in physical form are allowed to tender shares in open offer. However, such tendering shall be as per the provisions of the SEBI SAST Regulations. Shareholders holding shares in physical form who have not received the FOA, may participate in the offer by application in plain paper and approaching their broker indicating the details of Name, address, distinctive

valid share transfer form(s) duly filled and signed by the transferors (i.e., by all registered shareholders in same order and as per the specimen signatures registered with the Target Company) and duly witnessed at the appropriate place authorizing the transfer in favour of the Target Company;

any other relevant documents such as power of attorney, corporate authorization (including board resolution/specimen signature), notarized copy of death certificate and succession certificate or probated will, if the

TRS (Transaction Registration Slip) obtained from Broker evidencing the bidding on OTB platform by the

For further details, Shareholders are requested to refer to the section titled "Procedure for Acceptance and

Eligible Shareholders must ensure that the application (including plain paper application), along with the TRS and requisite documents, reach the Registrar to the Offer not later than 2 (two) working days from the closure of the Offer. If the signature(s) of the Eligible Shareholders provided in the FOA / plain paper application differs from the specimen signature(s) recorded with the Registrar of the Company or are not in the same order

All the changes to draft LOF suggested by SEBI vide their letter January 10, 2022 bearing reference number SEBI/HO/CFD/DCR2/P/OW/2022/01476/1, in terms of Regulation 16(4) of the SEBI SAST Regulations, have been

As on the date of this Offer Opening Public Announcement, no statutory approvals are required by the Acquirers to acquire the Equity Shares that are tendered pursuant to the Offer. However, the Offer would be subject to all

Capitalized terms used in this announcement, but not defined, shall have the same meaning assigned to them in the PA, DPS and

 $A copy of this Offer Opening \ Public \ Announcement \ shall \ also \ be \ available \ on \ the \ SEBI \ website \ at \ www.sebi.gov.in.$ 

rate Park, Guru Hargovindji Road, Chakala,

ibility for the information contained in this Announcement and also for the fulfilment of

Revised Schedule Wednesday, November 24, 2021

Wednesday, December 1, 2021

Wednesday, December 8, 2021 Wednesday, December 22, 2021

Monday, January 10, 2022

Wednesday, January 12, 2022

Wednesday, January 19, 2022

Wednesday, January 19, 2022

Tuesday, January 25, 2022 Thursday, January 27, 2022

Wednesday, February 9, 2022

Wednesday, February 23, 2022